For research use only. Not for therapeutic Use.
JB061 is a nonmuscle myosin inhibitor with IC50s of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II), respectively. JB061 poorly decreases ATPase activity (IC50>200 μM). JB061 shows cytotoxicity against COS-7 cells with an IC50 value of 39 μM[1].
JB061 (compound 6a) (40 μM; 24 h) inhibits cytokinesis in Cos-7 cells[1].
| Catalog Number | I042356 |
| Synonyms | 4-hydroxy-3-[N-[(3-methoxyphenyl)methyl]-C-methylcarbonimidoyl]chromen-2-one |
| Molecular Formula | C19H17NO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17NO4/c1-12(20-11-13-6-5-7-14(10-13)23-2)17-18(21)15-8-3-4-9-16(15)24-19(17)22/h3-10,21H,11H2,1-2H3 |
| InChIKey | MJXJTQZHVWSPLP-UHFFFAOYSA-N |
| SMILES | CC(=NCC1=CC(=CC=C1)OC)C2=C(C3=CC=CC=C3OC2=O)O |
| Reference | [1]. Smith JD, et al. Isoform selectivities of novel 4-hydroxycoumarin imines as inhibitors of myosin II. Eur J Med Chem. 2022 Dec 12;247:115008. |
